Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, Trinkaus K, Song SK, Cross AH Neurology. 2010 Jun 8; 74(23):1860-7. PMID: 20530322. Abstract CommentRecommendBookmarkWatch